Tanya Grun, MD
Family Medicine · Dallas, TXNPI 1023091014
Payments from drug & device makers
Across 233 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$778
- AbbVie$440
- Lilly USA, LLC$383
- Amarin Pharma, Inc.$290
- Takeda Pharmaceuticals U.S.A., Inc.$281
- Novo Nordisk$176
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,012100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $778 |
| AbbVie(2 entities) | 30 | $440 |
| Lilly USA, LLC | 24 | $383 |
| Amarin Pharma, Inc. | 20 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $281 |
| Novo Nordisk | 10 | $176 |
| GSK | 10 | $162 |
| Johnson & Johnson | 6 | $127 |
| Kowa Pharmaceuticals America, Inc. | 6 | $116 |
| Lundbeck LLC | 6 | $114 |
| Vanda Pharmaceuticals Inc. | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Esperion Therapeutics, Inc. | 6 | $95 |
| Abbott | 3 | $85 |
| Merck | 6 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $70 |
| Supernus Pharmaceuticals, Inc. | 4 | $64 |
| Bausch Health US, LLC | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Adlon Therapeutics L.p. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| AstraZeneca | 3 | $42 |
| Tris Pharma Inc | 2 | $36 |
| Mannkind Corporation | 2 | $34 |
| Astellas Pharma US Inc | 2 | $29 |
| Boston Scientific | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Medicure Pharma Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$4,012 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 14 | $183 |
| Baclofen | 13 | $118 |
| Atorvastatin Calcium | 19 | $92 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.